In Mylan Pharmaceuticals Inc. v. Galderma Laboratories, Inc., Civ. No. 10-892-LPS (D. Del. Mar. 24, 2011), Judge Stark construed two claim terms:
Term 1: “steady state blood levels of doxycycline of a minimum of 0.1 μg/ml and a maximum of 1.0 μg/ml”
Meaning: “steady state plasma concentrations of doxycycline of a minimum of 0.1 μg/ml and a maximum of 1.0 μg/ml”
Term 2: “steady state blood levels of doxycycline of between 0.3 μg/ml to 0.8 μg/ml”
Meaning: “steady state plasma concentrations of doxycycline of between 0.3 μg/ml to 0.8 μg/ml”